NEW YORK (GenomeWeb News) – The National Cancer Institute is offering to fund researchers studying ways of using emerging cellular, molecular, and genomics technologies in cancer care.
These research programs will assess these technologies for how they work in regards to quality of care, cost-effectiveness, influence on cancer outcomes, progression, survival, and mortality, and in other ways, NCI said.
One of the programs, under an R01 funding mechanism, does not specify the amount of funding available, and the second, an R21 grant program, will give up to $275,000 over a two-year period, and up to $200,000 in a single year.
The tools NCI wants assessed could include those that are already in use, as well as tools that are in late stages of development or in phases of the regulatory pipeline. Collaborations between health services researchers and in clinical and translational sciences are also encouraged.
Clinical tools that investigators seek to study should “be directly applicable to cancer prevention, early detection, diagnosis, or treatment,” NCI stated in a funding announcement. The research should be targeted to specific DNA or RNA sequences or other specific molecules or pathways, and they should relate to genomics, proteomics, or similar fields, NCI added.
Technologies researchers could consider include genetic tests for cancer risk; genotyping or molecular and biochemical assays; biomarker tests for early malignancy detection; molecular profiling and tumor imaging and biomarker-based tests for cancer recurrence; pharmacogenetic or molecular assays to predict treatment outcomes; RNA interference; and toxicity and efficacy biomarker assays for monitoring treatment and drug resistance.
More information about the R01 and R21 programs, called “Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies on Cancer Health Care Delivery,” may be found here and here.